Navigation Links
Soligenix Reports Third Quarter 2009 Financial Results
Date:11/13/2009

penses for the first nine months of 2009 were approximately $1.7 million, compared to $1.8 million for the first nine months of 2008.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix), formerly known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. orBec® is currently the subject of a confirmatory Phase 3 clinical trial for the treatment of acute GI GVHD and an NIH-supported, Phase 2, randomized, double-blind, placebo-controlled trial in the prevention of acute GVHD. Soligenix also expects to begin an NIH-supported Phase 1/2 clinical trial of SGX201 in radiation enteritis in the second half of 2009. Additionally, Soligenix has a Lipid Polymer Micelle (LPM(TM)) drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.

Through its Biodefense Division, Soligenix is developing biomedical countermeasures pursuant to the Project BioShield Act of 2004. Soligenix's lead biodefense product in development is a recombinant subunit vaccine called RiVax(TM) which is designed to protect against the lethal effects of exposure to ricin toxin. RiVax(TM) has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers. RiVax(TM) will also be the subject of a recent $9.4 million NIH grant received by the Company supporting development of new heat stable vaccines.

For further information regarding Soligenix, Inc., please visit the Company's website at www.solig
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), ... of chronic pain, announced the results of its annual ... was a transformational year in Relmada,s history and it ... company," said Sergio Traversa , chief executive officer ... on key financial, human resource and clinical development objectives ...
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Achim Noack ... administration for Stoller Group. In this position, Noack will ... on administrative matters, develop marketing strategy and supervise global ... , “Achim has tremendous knowledge and experience in ... Stoller Group. “His experience and innovative thinking will be ...
(Date:12/17/2014)... Once more, EMAAR has selected BioShaft ... water treatment plant to phase one of BayLaSun, a ... years ago Bioshaft successfully supplied and operated a packaged ... towers with an occupancy of 900 residences. The ... per day and was signed on September 16th, 2014, ...
Breaking Biology Technology:Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... Stephen Simes, chief executive,officer of BioSante Pharmaceuticals, Inc. ... featured in an exclusive interview with, http://www.wallst.net ... The interview,will be posted on http://www.wallst.net ... The interview will cover topics including BioSante,s market ...
... N.J., Sept. 24 New Brunswick,Scientific Co., Inc. ("NBS") ... the completion of the previously announced,merger transaction in which ... transaction. As a result of the merger, which was,approved ... 20, 2007,NBS, shareholders are entitled to receive $11.50 per ...
... Targets the Skin,s ... EL SEGUNDO, Calif., Sept. 24 With many ... and the,category of Internal Skincare(R), now Dr. Howard Murad, ... Inc. and author of,Wrinkle-Free Forever and The Cellulite Solution, ...
Cached Biology Technology:WallSt.net Announces Upcoming Interview with CEO of BioSante Pharmaceuticals 2New Brunswick Scientific Completes Merger Transaction with Eppendorf 2Murad Boosts Skin Immunity With the New Murad(R) Professional Line 2
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/5/2014)... 2014 Increased emphasis on product quality, ... testing and inspection technologies. The convergence of industries ... range of innovative test solutions. This trend is ... which is generally more inclined towards communication, media ... strategies of test equipment vendors will cater to ...
(Date:12/4/2014)... 3, 2014  Crossmatch™, a leading provider of ... DigitalPersona ® Pro Enterprise software and U.are.U ... throughout First Bank branch locations in ... and Virginia. First Bank, a progressive community ... North Carolina , selected the Crossmatch biometrics-based ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... Limited recently announced successful results in preclinical trials ... trials in humans this month to firstly test ... and later its effectiveness in treating the neuropathic ... of Melbourne's Department of Biochemistry and Molecular Biology ...
... Everyone knows that stem cells are controversial. Many people know that ... the body, from a red blood cell to a muscle cell ... cells continue to divide and renew themselves long after the point ... and the University of Washington offer one of the first clues ...
... the biggest questions in modern oceanography is how animals ... biologists at the Monterey Bay Aquarium Research Institute (MBARI) ... at least for animals that live on the deep ... hundreds of hours of deep-sea video, Bruce Robison and ...
Cached Biology News:Molecular miners find pain relief drugs from the sea 2Molecular miners find pain relief drugs from the sea 3Discovery suggests why stem cells run through stop signs 2'Sinkers' provide missing piece in deep-sea puzzle 2'Sinkers' provide missing piece in deep-sea puzzle 3'Sinkers' provide missing piece in deep-sea puzzle 4
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
... 75 x ... recommended for immunohistochemistry of paraffin-embedded sections, ... at one end, markings ... normal procedures, precleaned, ...
Donor feline serum and plasma...
Biology Products: